ProQR Therapeutics N.V.
PRQRProQR Therapeutics NV (NASDAQ: PRQR) is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer (CEO) Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer.
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
sepofarsen
Leber Congenital Amaurosis 10
QR-1123
Autosomal Dominant Retinitis Pigmentosa
QR-421a
Retinitis Pigmentosa
QR-010
Cystic Fibrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
sepofarsen | Phase 3 | Leber Congenital Amaurosis 10 | - | - |
QR-1123 | Phase 2 | Autosomal Dominant Retinitis Pigmentosa | - | - |
QR-421a | Phase 2 | Retinitis Pigmentosa | - | - |
QR-010 | Phase 2 | Cystic Fibrosis | - | - |